Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy.
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic joint inflammation and continuous immune cell infiltration in the synovium. These changes are linked to inflammatory cytokine release, leading to eventual destruction of cartilage and bone. During the last decade new therapeutic modalities have improved the prognosis, with the introduction of novel biological response modifiers including anti-TNFalpha CTLA4Ig and, more recently, anti-IL6. In the present study we looked at the immunological effects of these three forms of therapy. Serum, obtained from patients with RA was analyzed for TNFalpha, IL6, IL10, IFNgamma, and VEGF, and in parallel, circulating plasmacytoid and myeloid dendritic cells (DC) were enumerated before and after three infusions of the respective biological treatments. After treatment with anti-IL6, we found a significant reduction of IL6 and TNFalpha levels and the percentage of both DC subsets decreased. Although the results did not reach statistical significance for anti-TNFalpha treatment, similar trends were observed. Meanwhile, CTLA4Ig therapy led to the reduction IFNgamma levels only. None of the treatments modified significantly VEGF or IL10 levels. These findings may explain why patients with RA improve more rapidly on IL-6 therapy than with the other two modalities.
Marti
Luciana
L
Hospital Albert Einstein-Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil.
Golmia
Ricardo
R
Golmia
Andrea Pimentel Fonseca
AP
Paes
Angela Tavares
AT
Guilhen
Daiane Donna
DD
Moreira-Filho
Carlos Alberto
CA
Scheinberg
Morton
M
D000069594:Abatacept; D000328:Adult; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000276:immunology / Q000628:therapy*; D001691:Biological Therapy / Q000379:methods*; D017252:CD3 Complex / Q000032:analysis; D016207:Cytokines / Q000097:blood*; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects* / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D053650:Interleukin-3 Receptor alpha Subunit / Q000032:analysis; D015850:Interleukin-6 / Q000097:blood / Q000276:immunology; D018950:Lipopolysaccharide Receptors / Q000032:analysis; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000276:immunology; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D000906:Antibodies; D018501:Antirheumatic Agents; D017252:CD3 Complex; D016207:Cytokines; D018796:Immunoconjugates; D053650:Interleukin-3 Receptor alpha Subunit; D015850:Interleukin-6; D018950:Lipopolysaccharide Receptors; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; D016753:Interleukin-10; D000069594:Abatacept; D007371:Interferon-gamma